
Michel Delforge, MD, PhD, discusses the rationale for conducting the CARTITUDE-4 trial investigating cilta-cel in lenalidomide-refractory multiple myeloma.

Your AI-Trained Oncology Knowledge Connection!


Michel Delforge, MD, PhD, discusses the rationale for conducting the CARTITUDE-4 trial investigating cilta-cel in lenalidomide-refractory multiple myeloma.

Michel Delforge, MD, PhD, discusses the efficacy of cilta-cel in CARTITUDE-4 vs alternative approaches for lenalidomide-refractory myeloma.

Published: October 29th 2024 | Updated: